Alcohol Use Disorder Market Size is Expected to Grow at a CAGR of 13.6% by 2034

The Alcohol Use Disorder Market was valued at approximately USD 1100 Million in 2025 and is projected to grow at a CAGR of 13.6% during the forecast period (2025-2034). DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Alcohol Use Disorder Market Landscape.

By analyzing historical data, current Alcohol Use Disorder Market Dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Alcohol Use Disorder Market is increasingly guided by biomarker-driven strategies. Alcohol Use Disorder (AUD) is a chronic medical condition characterized by an impaired ability to stop or control alcohol consumption despite its harmful consequences on health, relationships, or work. It ranges from mild to severe and includes what is commonly known as alcohol abuse, dependence, or alcoholism. Individuals with AUD often develop tolerance (needing more alcohol to feel the same effects) and withdrawal symptoms (like anxiety, sweating, or nausea) when they try to reduce or stop drinking.

DelveInsight’s report, “Alcohol Use Disorder Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Alcohol Use Disorder Market landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Alcohol Use Disorder Market Dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Alcohol Use Disorder Market Outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Alcohol Use Disorder Market Forecast

Some of the key facts of the Alcohol Use Disorder Market Report

• The leading Alcohol Use Disorder Companies, such as Alkermes, Lundbeck, Otsuka Pharmaceutical, Adial Pharmaceuticals, Beckley Psytech, Atai Life Sciences, MediciNova, and others.

• Promising Alcohol Use Disorder Therapies such as Sunobinop, ASP8062, GET73, Gabapentin Enacarbil, Mazdutide, BPL-003, Arbaclofen Placarbil, Ibudilast, AD04 (ondansetron), XR-NTX, and others.

• The Alcohol Use Disorder Market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching multiple-stage Alcohol Use Disorder Pipeline products will significantly revolutionize the Alcohol Use Disorder Market Dynamics.

Alcohol Use Disorder Overview

Alcohol Use Disorder (AUD) is a serious and progressive brain disorder that affects how individuals think, feel, and behave around alcohol. It occurs when a person becomes unable to manage their drinking habits, leading to compulsive alcohol use despite the awareness of its harmful consequences.

Get a Free sample for the Alcohol Use Disorder Market Report @ https://www.delveinsight.com/report-store/alcohol-use-disorder-market 

Key Trends in Alcohol Use Disorder Therapeutics Market

• Rising Focus on Novel Mechanisms of Action 

Pharmaceutical companies are increasingly exploring innovative mechanisms that target the brain’s reward and stress pathways to reduce alcohol cravings and dependency. Research is moving beyond traditional GABA and opioid receptor targets toward glutamatergic modulation and neuroinflammation pathways.

• Increased Use of Combination Therapies

Combining pharmacological treatments with behavioral therapies is becoming a preferred strategy for improving treatment adherence and patient outcomes. This integrated approach enhances the effectiveness of recovery programs and reduces relapse rates.

• Growing Pipeline of Emerging Therapies

Multiple late-stage and early-phase pipeline drugs are under development, offering hope for improved efficacy and safety profiles. Companies are focusing on long-acting injectables and novel oral agents that address both withdrawal management and relapse prevention.

• Advancements in Digital Therapeutics and Remote Monitoring

The integration of digital health tools, including smartphone-based interventions, telehealth consultations, and AI-driven monitoring platforms, is transforming patient engagement and long-term care management in Alcohol Use Disorder.

Alcohol Use Disorder Epidemiology

The Alcohol Use Disorder epidemiology chapter in the report provides historical as well as forecasted data in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034. The Alcohol Use Disorder epidemiology is segmented with detailed insights into Total Alcohol Use Disorder Incident cases, Alcohol Use Disorder Gender-specific Incident cases, Alcohol Use Disorder Severity-specific Incident Cases, and Alcohol Use Disorder Origin-specific Incident cases.

Alcohol Use Disorder Epidemiology Segmentation in the 7MM

The Alcohol Use Disorder Market Report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into-

• 12-month Diagnosed Prevalent cases of Alcohol Use Disorder
• Gender-specific Diagnosed Prevalent cases of Alcohol Use Disorder
• Age-specific Diagnosed Prevalent cases of Alcohol Use Disorder
• Severity-specific Diagnosed Prevalent cases of Alcohol Use Disorder
• Total Treated Cases of Alcohol Use Disorder

Download the report to understand which factors are driving Alcohol Use Disorder Epidemiology trends @ Alcohol Use Disorder Epidemiology Forecast

Recent Developments in the Alcohol Use Disorder Treatment Landscape

• In October 2025, Novo Nordisk A/S initiated a study to evaluate the effects of NNC0194-0499, cagrilintide, and semaglutide on liver damage and alcohol consumption in participants with alcoholic liver disease. Participants are randomly assigned to receive NNC0194-0499, semaglutide, cagrilintide, or a placebo (“dummy” medicine) in various treatment combinations. The clinical study is designed to run for approximately 39 weeks.

Alcohol Use Disorder Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential Alcohol Use Disorder drugs recently launched in the Alcohol Use Disorder market or expected to get launched during the study period. The analysis covers Alcohol Use Disorder Market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Alcohol Use Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Alcohol Use Disorder Companies and Therapies

• Imbrium Therapeutics: Sunobinop
• Laboratorio Farmaceutico Ct S.r.l.: GET73
• NYU Langone Health: Phytocannabinoid cannabidiol (CBD)
• Eli Lilly and Company: Mazdutide
• Beckley Psytech Limited: BPL-003
• Indivior Inc.: Arbaclofen Placarbil

To know more about Alcohol Use Disorder Companies working in the treatment market, visit @ Alcohol Use Disorder Clinical Trials and Therapeutic Assessment

Alcohol Use Disorder Market Drivers

• Rising Global Prevalence of Alcohol Dependence

The increasing incidence of harmful alcohol consumption and dependence across diverse populations has significantly fueled the demand for effective treatment solutions, boosting the Alcohol Use Disorder market growth.

• Growing Awareness and Early Diagnosis

Expanding public health initiatives, awareness campaigns, and education programs are encouraging early diagnosis and intervention, leading to improved treatment uptake and higher market penetration.

• Advancements in Pharmacological Therapies

The development of innovative drugs targeting novel neurological pathways is transforming the treatment landscape. Emerging therapies with improved safety and efficacy profiles are creating new opportunities for market expansion.

• Integration of Digital Health Technologies

The adoption of digital therapeutics, telemedicine platforms, and AI-based monitoring tools has enhanced patient adherence, engagement, and personalized treatment delivery, driving the evolution of modern AUD management.

Alcohol Use Disorder Market Barriers

• High Relapse Rates and Limited Long-Term Efficacy

Despite the availability of several pharmacological and behavioral treatments, relapse remains a significant challenge. Many patients struggle to maintain long-term abstinence, limiting the overall effectiveness of current therapies.

• Social Stigma and Low Treatment-Seeking Behavior

The persistent social stigma associated with alcohol dependence discourages individuals from seeking professional help. This underreporting and low diagnosis rate hinder market growth and delay timely intervention.

• Limited Availability of Effective Pharmacotherapies

Only a few approved drugs—such as naltrexone, acamprosate, and disulfiram—are currently available, and their efficacy varies widely among patients. This lack of universally effective medications restricts clinicians' therapeutic options.

• Challenges in Patient Adherence

Treatment adherence is often low due to side effects, lengthy treatment durations, and psychological dependence. Non-compliance with prescribed regimens reduces the potential success rate of pharmacological interventions.

Scope of the Alcohol Use Disorder Market Report

• Coverage- 7MM

• Study Period-2020-2034

• Alcohol Use Disorder Companies- Alkermes, Lundbeck, Otsuka Pharmaceutical, Adial Pharmaceuticals, Beckley Psytech, Atai Life Sciences, MediciNova, and others.

• Alcohol Use Disorder Therapies- Sunobinop, ASP8062, GET73, Gabapentin Enacarbil, Mazdutide, BPL-003, Arbaclofen Placarbil, Ibudilast, AD04 (ondansetron), XR-NTX, and others.

• Alcohol Use Disorder Therapeutic Assessment: Alcohol Use Disorder current marketed and Alcohol Use Disorder emerging therapies

• Alcohol Use Disorder Market Dynamics: Alcohol Use Disorder market drivers and Alcohol Use Disorder market barriers

• Alcohol Use Disorder Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Alcohol Use Disorder Unmet Needs, KOL’s views, Analyst’s views, Alcohol Use Disorder Market Access and Reimbursement

Discover more about therapies set to grab major Alcohol Use Disorder Market Share @ Alcohol Use Disorder Treatment Market

Table of Contents

1 Key Insights

2 Alcohol Use Disorder Market Report Introduction

3 Alcohol Use Disorder Executive Summary

4 Key Events

5 Alcohol Use Disorder Epidemiology and Market Forecast Methodology

6 Alcohol Use Disorder Market Overview at a Glance

7 Alcohol Use Disorder: Disease Background and Overview

8 Alcohol Use Disorder Treatment and Medical Management

9 Alcohol Use Disorder Epidemiology and Patient Population

10 Alcohol Use Disorder Patient Journey

11 Alcohol Use Disorder Marketed Drugs

12 Key Cross Competition

13 Alcohol Use Disorder Emerging Therapies

14 Alcohol Use Disorder: Seven Major Market Analysis

15 Alcohol Use Disorder KOL Views

16 Alcohol Use Disorder SWOT Analysis

17 Alcohol Use Disorder Unmet Needs

18 Alcohol Use Disorder Market Access and Reimbursement

19 Appendix

20 DelveInsight Capabilities

21 Disclaimer

22 About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.